Amphotericin B Inhibits Enterovirus 71 Replication by Impeding Viral Entry

Fengwen Xu1*, Xiaoxiao Zhao1*, Siqi Hu1, Jian Li1, Lijuan Yin1, Shan Mei1, Tingting Liu1, Ying Wang1, Lili Ren1, Shan Cen2, Zhendong Zhao1, Jianwei Wang1, Qi Jin1, Chen Liang1,3, Bin Ai4 & Fei Guo1

Enterovirus 71 (EV71) infection causes hand-foot-and-mouth disease that leads to cardiopulmonary complications and death in young children. There is thus an urgent need to find new treatments to control EV71 infection. In this study, we report potent inhibition of EV71 by a polyene antibiotic Amphotericin B. Amphotericin B profoundly diminished the expression of EV71 RNA and viral proteins in the RD cells and the HEK293 cells. As a result, EV71 production was inhibited by Amphotericin B with an EC50 (50% effective concentration) of 1.75 μM in RD cells and 0.32 μM in 293 cells. In addition to EV71, EV68 was also strongly inhibited by Amphotericin B. Results of mechanistic studies revealed that Amphotericin B targeted the early stage of EV71 infection through impairing the attachment and internalization of EV71 by host cells. As an effective anti-fungi drug, Amphotericin B thus holds the promise of formulating a novel therapeutic to treat EV71 infection.

Enterovirus 71 (EV71) is a member of the Picornaviridae family. Its main target population are children who, upon infection with EV71, develops rashes, diarrhea and hand-foot-and-mouth disease (HFMD)1–3. In severe cases, EV71 infection leads to central nervous system diseases4–6. Since the isolation of EV71 in 19697, EV71 infections have caused a series of epidemics in the western Pacific region countries, including China, Japan, Malaysia, and Singapore8–12.

EV71 has a single-stranded positive-sense RNA genome that encodes a single precursor protein. This precursor protein is cleaved by viral protease into mature structural and non-structural proteins. Several cell surface proteins have been reported to either serve as the receptors of EV71, including human P-selectin glycoprotein ligand-1 (PSGL-1), scavenger receptor B2 (SCARB2) and heparan sulfate13–16, or to promote EV71 entry such as vimentin17.

A number of drugs have been reported to inhibit of EV71 infection. For example, the entry or uncoating of EV71 is impaired by Pleconaril, picodavir, and BPROZ-19418–20. Rupintrivir inactivates the proteases of human rhinovirus and EV7121–24. The attachment of EV71 to cells is strongly inhibited by glycosaminoglycans25. DTI-P-22 and aurintricarboxylic acid inhibit viral RNA-dependent RNA polymerase 3D26,27. The RNA polymerase of EV71 is inhibited by nucleoside analogs such as ribavirin, 2′-C-methylcytidine, and N-6-modified purine28–31. However, none of these drugs have been approved for clinical treatment of EV71 infection. Discovery of new EV71 inhibitors is thus urgently needed. Long term and high cost of antiviral development make the use of drug products in low- and middle-income countries extremely limited. It has therefore been an important alternative strategy to discover new applications for old drugs. In this context, we have tested Amphotericin B as a potential EV71 inhibitor.

Amphotericin B has been used to treat serious systemic fungal infection such as Aspergillosis since the 1950s. Multiple clinical formulations of Amphotericin B are currently used to treat a growing number of fungal infections32. Amphotericin B kills fungi and single cell parasites like Leishmania spp by preferentially binding to ergosterol than cholesterol. In addition, Amphotericin B also exhibits antiviral activity against vesicular stomatitis virus
Amphotericin B prevents the binding and internalization of EV71 virions to target cells. To further identify which step of EV71 infection was inhibited by Amphotericin B, we examined binding of EV71 particles to target cells and viral internalization. Virus binding assay was performed by incubating EV71 viruses with RD or 293 cells with or without Amphotericin B at 4 °C as previously described. After extensive washing to remove unbound viruses, amounts of viruses that were associated with target cells under Amphotericin B treatment decreased to less than 60% of that measured in the absence of Amphotericin B (Fig. 5, Bound). Protease treatment decreased to less than 60% of that measured in the absence of Amphotericin B (Fig. 5, Bound). These data suggest that Amphotericin B potently inhibits EV71 infection in both RD and 293 cells.

Amphotericin B pretreatment does not affect the infectivity of EV71 virions. It has been previously shown that pretreatment of enveloped viruses such as HIV-1 with Amphotericin B severely inhibited viral infection, whereas pretreatment of the target cells with Amphotericin B exerted minimal effect. To test whether Amphotericin B inhibits HIV-1 and EV71 by a similar mechanism, we treated EV71 virions, but not the target cells, with different concentrations of Amphotericin B before applying EV71 to RD or 293 cells. In contrast to the profound inhibition of EV71 infection when target cells were pretreated with Amphotericin B as shown in Fig. 1, pretreatment of EV71 virions alone did not affect virus infection in RD (Fig. 3a) or 293 cells (Fig. 3b). These data suggest that pretreatment of EV71 virions did not affect structure of virions, and that Amphotericin B inhibits HIV-1 and EV71 by different mechanisms.

Amphotericin B inhibits the early stage of EV71 infection. Amphotericin B has been shown to inhibit different viruses at various stages of their life cycles. We therefore examined which step of EV71 lifecycle was affected by Amphotericin B. RD cells or 293 cells were infected with EV71 in the absence or presence of Amphotericin B, and viral protein expression was measured by Western blotting. Expression of EV71 VP1 and VP2 was decreased at the earliest detectable time point (6 hpi in RD and 8 hpi in 293) (Fig. 4a,b). We next assessed the inhibition by quantifying the viral RNA through quantitative RT-PCR at 2, 4, 6, 8, and 10 h post infection (Fig. 4c). The results showed that the amount of EV71 RNA in the infected cells was reduced by 2 hpi under Amphotericin B treatment. These data suggest that Amphotericin B impedes an early step of EV71 life cycle.
cell surface (Fig. 5, Internal). The results showed significant reduction of EV71 internalization by Amphotericin B. We also examined the expression of EV71 receptor SCARB2 by western blotting and found that SCARB2...
expression was not affected by Amphotericin B (Fig. 5c). In addition, the internalized viruses were quantitated in plaque assay. As shown in Fig. 5d, the internalized viruses were reduced as a result of Amphotericin B treatment. Together, these data suggest that Amphotericin B impairs the binding and internalization of EV71 virus to host cells without affecting viral receptor expression.

**Amphotericin B inhibits EV68 infection.** Over 1000 cases of severe respiratory diseases in pediatric patients were reported to associate with enterovirus 68 (EV68) infection in the fall of 2014. We have therefore measured the effect of Amphotericin B on EV68 infection. RD cells were infected with EV68 in the absence or presence of Amphotericin B. Full-length blots are presented in Supplementary Fig. 3. The data represented the copy number of EV68 RNA. Results shown are the average of three independent experiments. Error bars represent SD (*P < 0.05, **P < 0.01, t test).

**Discussion**

A number of EV71 outbreaks have been reported since the first case of EV71 infection was documented in California in 1969. Several recent EV71 outbreaks occurred in Asian countries and have resulted in substantial mortalities. Effective antivirals to treat and control EV71 infection are still lacking, although efforts in this direction are under way. In this study, we have demonstrated that Amphotericin B strongly inhibits EV71...
infection. Amphotericin B showed an EC50 of 1.75 μM in RD cells and 0.32 μM in 293 cells, a CC50 of 7.37 μM in RD cells and 14.5 μM in 293 cells. In addition to EV71, Amphotericin B also potently inhibits EV68, a closely related enterovirus that has caused severe respiratory disease and is becoming a globally emerging pathogen in humans.

Amphotericin B inhibits HIV-1 and EV71 by different mechanisms. Different from HIV-1, pretreatment of EV71 virions with Amphotericin B did not affect EV71 infection. Upon binding to HIV-1 virion lipid bilayer, Amphotericin B had no effect on the levels of cholesterol, but may prevent the Env glycoprotein from undergoing conformational changes that are necessary to trigger membrane fusion. Alternatively, Amphotericin B-mediated inhibition could be due to direct binding of the compound to gp120 or to the ectodomain of gp4143. We did not observe any effect of Amphotericin B pretreatment on EV71 virions, likely because EV71 is a nonenveloped virus.

Given the prolonged process and the high costs to develop a new drug for clinical use, using the clinically approved drugs to treat EV71 infection is considered as an economical and efficient strategy. Amphotericin B is an antimicrobiant agent, and has been used to treat many serious systemic fungal infections. Although Amphotericin B and its derivatives have been reported to inhibit VSV, HSV-1, Sindbis virus, vaccinia virus, HIV-1 and promote influenza virus replication, the effect of Amphotericin B on EV71 has not been reported. In this study, we observed strong inhibition of EV71 infection by Amphotericin B not only in RD but also in 293 cells. Amphotericin B also reduced infection of EV68. Results of virus binding assay suggested that Amphotericin B impaired the early phase of EV71 infection. This drug directly blocked the attachment and internalization of EV71 to host cells.

Figure 5. Amphotericin B impedes the binding and internalization of EV71 virions to host cells. EV71 was incubated with Amphotericin B pretreated RD (a) and 293 cells (b). Then background, bound, internal cells (described in materials and methods) were lysed for RNA extraction. Viral RNA was quantified by semi-RT PCR (upper panel) and viral RNA copy number was quantified by quantitative RT-PCR (lower panel). The results are plotted relative to virus background in DMSO treated cells. The data represent 3 independent experiments, and error bars represent SD (*P < 0.05, **P < 0.01, t test). (c) Levels of SCARB2 expression in background, bound, internal cells were determined by Western blotting. Full-length gels are presented in Supplementary Fig. 4. (d) The internalized viral titers were determined in plaque assays. The internal cells were collected at 10 hpi, and proceeded plaque assay after frozen and thaw. Cells treated with DMSO were set as 100%. The data represent 3 independent experiments, and error bars represent SD (**P < 0.01, t test).
Side effects have been observed with high-dose amphotericin B treatment. Yet, these side effects are often transient and reasonably well tolerated in HIV-1 patients. In the context of cancer chemotherapy, the benefits of amphotericin B treatment outweigh the adverse side effects. Several improvements have been made for Amphotericin B therapy. For example, liposomal formulation of Amphotericin B improved tolerability while maintaining treatment efficacy in patients suffering infections of fungi and HIV-1. Importantly, Amphotericin B derivates such as MS-8209 (an N-methylglucamine salt of 1-deoxy-1-amino-4, 6-O-benzylidene-D-fructosyl Amphotericin B), AmBMU and AmBAU (the urea derivatives, Amphotericin B methyl urea and Amphotericin B amino urea) have much less toxicity (over 60 fold less) and deter the development of resistance. These low-toxicity derivates hold the potential to treat young children with EV71 infection.

The primary goal of EV71 treatment is to prevent severe and fatal clinical outcomes. Our work supports the utility of Amphotericin B, an approved antibiotic, as a potential drug candidate to treat severe EV71 infections. Preclinical profiling is expected to determine the feasibility of clinical development of Amphotericin B as an EV71 therapeutic.

Material and Methods

Cell lines, viruses, drugs, and antibodies. Human muscular rhabdomyosarcoma (RD) cells and human embryonic kidney 293 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS supplemented with L-glutamine, penicillin and streptomycin (Gibco BRL, Grand Island, NY, USA).

EV71 is a Fuyang strain (GenBank accession no. FJ439769.1). To conduct virus infections, cells were infected with EV71 at different MOIs (multiplicity of infection). Unbound viruses were washed off 2 h after infection. The enterovirus 68 (EV68) strain that was used in this study is a Beijing strain (GenBank accession no. KF726085). The reverse genetic system was utilized to produce influenza virus A/WSN/33 (H1N1)57.

Amphotericin B was purchased from Sigma–Aldrich. Mouse anti-VP1 antibody was purchased from Abnova, mouse anti-EV71 antibody from Millipore, anti-Actin antibody from Proteintech, anti-SCARB2 antibody from R&D systems, IRD Fluor 800-labeled IgG secondary antibodies from Li-Cor Inc., Lincoln, NE. The anti-EV68 3C antibody was obtained as previously described58.

EV71 infection and inhibition assay in RD and 293 cells. RD or 293 cells were treated with DMSO or Amphotericin B of various concentrations for 2 h prior to EV71 infection at the indicated MOIs. Each infection was performed in triplicate. Cell viability was measured by performing CellTiter-Glo® Luminescent Cell Viability Assay (Promega). Levels of viral proteins and viral RNA were determined by Western blotting and quantitative real-time PCR (qRT-PCR).
**Virus titration.** Virus titers were measured in the plaque assay. Briefly, RD cells were seeded into 6-well plates. Infections were conducted with viruses of 10-fold serial dilutions (10^-1 to 10^-4). Infection was carried out for 2 h at 37°C. The supernatants were then replaced with DMEM containing 1% agarose. 3 days after, the overlay medium was discarded. Cells were fixed in 4% paraformaldehyde followed by staining with Crystal violet. Viral plaques were scored by visual counting.

**Western blotting.** Cells were first harvested and then lysed in RIPA buffer containing 150 mM NaCl, 25 mM Tris (pH 7.4), 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA, 1 mM EGTA and a proteasine inhibitor cocktail (Roche). Proteins were separated on the 12% SDS-PAGE, and then transferred onto the nitrocellulose membrane (Millipore). After incubating in 5% milk, the membranes were probed with primary antibodies at 4°C for overnight. The corresponding IRDye™ secondary antibodies were then applied to the membranes (Odssey). After extensive washing, the membranes were scanned and analyzed using an Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE).

**Quantitative real-time PCR.** Total RNA were extracted from the EV71 infected cells using the RNAeasy Mini kit (Qiagen). Reverse transcriptions were then carried out using the Superscript First-Strand Synthesis System (Invitrogen). Viral RNA copy number was quantified by real-time PCR using Bio-Rad CFX96 touch q-PCR system. To generate a standard curve for cycle thresholds versus copy numbers, the pEGFP-VP1 plasmid was serially diluted to different concentrations. Primers for the amplification of VP1 gene were 5′-AGATAGGGTGCCGATGTAATTGAAAG-3′ and 5′-TAGCATTTGATGATGCTCCAAATTTCAG-3′.

**Virus binding assay.** Virus binding was assessed as previously described with some modifications. Briefly, RD cells were seeded in 6-well plates (8 × 10^5 cells/well). The next day, cells were first treated with DMSO or Amphotericin B for 2 h, and then washed with cold PBS, followed by incubation with 1 ml of binding buffer (PBS containing 1% BSA and 0.1% sodium azide) for 10 min on ice. Cells were then incubated with viruses at the indicated MOI for 1 h on ice. One group of cells was washed with PBS to remove unbound viruses and used to determine levels of bound virions (Bound). The second group of cells were treated with trypsin for 3 minutes to remove bound virions and the results serve as the background of the assay (Background). The third group of cells were cultured at 37°C for one hour to allow virus internalization before treated with trypsin to remove any virions that still bound to cell surface (Internal). Total RNA was then extracted and the levels of viral RNA were determined by quantitative RT-PCR. Three independent virus binding experiments were performed for each condition.

**References**

1. Hagiwara, A., Tagaya, I. & Yoneyama, T. Epicardial of hand, foot and mouth disease associated with enterovirus 71 infection. *Intervirology* 9, 60–63 (1978).
2. Ho, M. et al. An epidemic of enterovirus 71 infection in Taiwan. *Taiwan Enterovirus Epidemic Working Group. N Engl J Med* 341, 929–935, doi: 10.1056/NEJM19990223411301 (1999).
3. Tagaya, I., Takayama, R. & Hagiwara, A. A large-scale epidemic of hand, foot and mouth disease associated with enterovirus 71 infection in Japan in 1978. *Ipn J Med Sci Biol* 34, 191–196 (1981).
4. Zhang, Y. C. et al. Clinicopathologic features and molecular analysis of enterovirus 71 infection: report of an autopsy case from the epidemic of hand, foot and mouth disease in China. *Pathol Int* 62, 565–570, doi: 10.1111/j.1440-1827.2012.02837.x (2012).
5. Chang, L. Y. et al. Neurodevelopment and cognition in children after enterovirus 71 infection. *N Engl J Med* 356, 1226–1234, doi: 10.1056/NEJMoa065954 (2007).
6. Xue, J. et al. EV71: an emerging infectious disease vaccine target in the Far East? *Vaccine* 28, 3516–3521, doi: 10.1016/j.vaccine.2010.03.003 (2010).
7. Schmidt, N. J., Lennette, E. H. & Ho, H. H. An apparently new enterovirus isolated from patients with disease of the central nervous system. *J Infect Dis* 129, 304–309, doi: 10.1093/infdis/129.3.304 (1974).
8. Solomon, T. et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. *Lancet Infect Dis* 10, 778–790, doi: 10.1016/S1473-3099(10)70194-8 (2010).
9. Wang, S. M. & Liu, C. C. Enterovirus 71: epidemiology, pathogenesis and management. *Expert Rev Anti Infect Ther* 7, 735–742, doi: 10.1586/eri.09.45 (2009).
10. AbuBakar, S. et al. Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. *Virus Res* 61, 1–9, doi: 10.1016/S0168-1702(99)00019-2 (1999).
11. Hosoya, M. et al. Genetic diversity of enterovirus 71 associated with hand, foot and mouth disease epidemics in Japan from 1983 to 2003. *Pediatr Infect Dis J* 25, 691–694, doi: 10.1097/01.inf.0000227959.89339.e (2006).
12. Ding, N. Z. et al. Appearance of mosaic enterovirus 71 in the 2008 outbreak of China. *Virus Res* 145, 157–161, doi: 10.1016/j.viruses.2009.06.006 (2009).
13. Nishimura, Y. et al. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. *PLoS Pathog* 9, e1003511, doi: 10.1371/journal.ppat.1003511 (2013).
14. Tan, C. W., Poh, C. L., Sam, I. C. & Chan, Y. F. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. *J Virol* 87, 611–620, doi: 10.1128/JVI.02226-12 (2013).
15. Yamayoshi, S. et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. *Nat Med* 15, 798–801, doi: 10.1038/nm.1992 (2009).
16. Liu, Y. & Rossmann, M. G. The cellular receptor for enterovirus 71. *Protein Cell* 5, 655–657, doi: 10.1007/s13238-014-0092-6 (2014).
17. Du, N. et al. Cell surface vimentin is an attachment receptor for enterovirus 71. *J Virol* 88, 5816–5833, doi: 10.1128/JVI.03826-13 (2014).
18. Barnard, D. L. et al. *In vitro* activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. *Antimicrob Agents Chemother* 48, 1766–1772, doi: 10.1128/AAC.48.5.1766-1772.2004 (2004).
19. Shih, S. R. et al. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. *Antimicrob Agents Chemother* 48, 3523–3529, doi: 10.1128/AAC.48.9.3523-3529.2004 (2004).
20. De Colibus, L. et al. More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. *Nat Struct Mol Biol* 21, 282–288, doi: 10.1038/nsmb.2769 (2014).
21. Matthews, D. A. et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Pro Natl Acad Sci USA 96, 11000–11007, doi: 10.1073/pnas.96.20.11007 (1999).

22. Lu, G. et al. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol 85, 10319–10331, doi: 10.1128/JVI.00787-11 (2011).

23. Dragovich, P. S. et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties at L-glutamine replacements. J Med Chem 42, 1213–1224, doi: 10.1021/jm805384y (2009).

24. Zhang, X. et al. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antiviral Res 97, 264–269, doi: 10.1016/j.antiviral.2012.12.029 (2013).

25. Pourianfar, H. R., Poh, C. L., Fecondo, J. & Grollo, L. Amphotericin forms an extramembranous and fungicidal sterol sponge. Antimicrob Agents Chemother 58, 1519–1527, doi: 10.1128/AAC.00374-14 (2014).

26. Davis, S. A. et al. Nontoxic antimicrobials that evade drug resistance. Nat Chem Biol 10, 400–406, doi: 10.1038/nchembio.1496 (2014).

27. Wu, J., Ng, M. M. & Chu, J. J. Developments towards antiviral therapies against enterovirus 71. J Virol 86, 2121–2131, doi: 10.1128/JVI.00610-11 (2012).

28. Cole, T. et al. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. J Virol 88, 11915–11923, doi: 10.1128/JVI.01207-14 (2014).

29. Bellmann, R., Cleary, J. D. & Sterba, J. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B. Clin Adv Hematol Oncol 7, 1–8 (2009).

30. Petersen, J. et al. Nontoxic antimicrobials that evade drug resistance. Nat Chem Biol 10, 400–406, doi: 10.1038/nchembio.1496 (2014).

31. Deng, C. L. et al. Amphotericin B methyl ester: evidence for Vpu dependence. J Virol 82, 9776–9781, doi: 10.1128/JVI.00917-08 (2008).

32. Jordan, G. W., Humphreys, S. & Zee, Y. C. Effect of amphotericin B methyl ester on vesicular stomatitis virus morphology. Antimicrob Agents Chemother 33, 340–341, doi: 10.1128/AAC.33.1.340-341 (1978).

33. Kessler, H. A., Dixon, J., Howard, C. R., Tsiquaye, K. & Zuckerman, A. J. Effects of amphotericin B on hepatitis B virus. Antimicrob Agents Chemother 20, 826–833, doi: 10.1128/AAC.20.6.826 (1981).

34. Kessler, H. A., Dixon, J., Howard, C. R., Tsiquaye, K. & Zuckerman, A. J. Effects of amphotericin B on hepatitis B virus. Antimicrob Agents Chemother 20, 826–833, doi: 10.1128/AAC.20.6.826 (1981).

35. Pleskoff, O., Seman, M. & Alizon, M. Amphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding effect on virus-cell fusion but not on cell-cell fusion. J Virol 69, 570–574 (1995).

36. Stevens, N. M., Engle, C. G., Fisher, P. B., Meichls, W. & Schaffner, C. P. In vivo antitherapeutic activity of water-soluble amphotericin B methyl ester. Arch Virol 48, 391–394 (1975).

37. Jordan, G. W. & Seet, E. C. Antiviral effects of amphotericin B methyl ester. Antimicrob Agents Chemother 3, 199–204, doi: 10.1128/AAC.13.2.199 (1978).

38. Seok, H. et al. Disseminated Talaromyces marneffei and Mycobacterium intracellulare coinfection in an HIV-infected patient. Int J Infect Dis, doi: 10.1016/j.ijid.2015.07.020 (2015).

39. Mahajan, R. et al. Combination Treatment for Visceral Leishmaniasis Patients Cofected with Human Immunodeficiency Virus in India. Clin Infect Dis, doi: 10.1093/cid/civ530 (2015).

40. Roethl, E. et al. Antimycotic-antibiotic amphotericin B promotes influenza virus replication in cell culture. J Virol 85, 11139–11145, doi: 10.1128/JVI.00479-11 (2011).

41. Mahajan, R. et al. Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants. J Biol Chem 281, 28699–28711, doi: 10.1074/jbc.M603609200 (2006).

42. Petersen, J. et al. The major cellular sterol regulatory pathway is required for Andes virus infection. PLoS Pathog 10, e1003911, doi: 10.1371/journal.ppat.1003911 (2014).

43. Cordey, S. et al. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog 8, e1002826, doi: 10.1371/journal.ppat.1002826 (2012).

44. Khan, E. Enterovirus D68: acute respiratory illness and the 2014 outbreak. Emerg Med Clin North Am 33, e19–e32 (2015).

45. Waghmare, A. et al. Clinical disease due to enterovirus D68 in adult hematologic malignancy patients and hematopoietic cell transplant recipients. Blood 125, 1724–1729, doi: 10.1182/blood-2014-12-616516 (2015).

46. da Silva, E. E., Winkler, M. T. & Pallansch, M. A. Role of enterovirus 71 in acute flaccid paralysis after the eradication of poliovirus in Brazil. Emerg Infect Dis 2, 231–233, doi: 10.3201/eid0203.960312 (1996).

47. Gilbert, G. L. et al. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J 7, 484–488 (1988).

48. Khetrsurin, N., Lamonte-Fowlkes, A., Oberst, S. & Pallansch, M. A. Enterovirus surveillance–United States, 1970–2005. MMWR Surveill Summ 55, 1–20 (2006).

49. Wu, J., Ng, M. M. & Chu, J. J. Development towards antiviral therapies against enterovirus 71. Drug Discov Today 15, 1041–1051, doi: 10.1016/j.drudis.2010.08.008 (2010).

50. McKinsey, D. et al. Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 111, 655–659, doi: 10.7326/0003-4819-111-8-655 (1989).

51. Flemming, D. et al. Inhibition of HIV replication by liposomal encapsulated amphotericin B. Antiviral Res 11, 119–125, doi: 10.1016/j.antiviral.2000.04.023 (1999).

52. Klavestad, P. et al. Effects of MS-8209, an amphotericin B derivative, on tumor necrosis factor alpha synthesis and human immunodeficiency virus replication in macrophages. Antimicrob Agents Chemother 44, 405–407, doi: 10.1128/AAC.44.2.405-407 (2000).

53. Anderson, T. M. et al. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol 10, 400–406, doi: 10.1038/nchembio.1496 (2014).

54. Davis, S. A. et al. Nontoxic antimicrobials that evade drug resistance. Nat Chem Biol 11, 481–487, doi: 10.1038/nchembio.1821 (2015).

55. Ran, Z. et al. In vitro and in vivo replication of influenza A H1N1 WSN3 viruses with different M1 proteins. J Gen Virol 94, 884–895, doi: 10.1099/vir.0.046219-0 (2013).

56. Xiang, Z. et al. Enterovirus 68 3C protease cleaves TRIF to attenuate antiviral responses mediated by Toll-like receptor 3. J Virol 88, 6650–6659, doi: 10.1128/JVI.03138-13 (2014).
Acknowledgements

This study was supported by funds from the Ministry of Science and Technology of China (2012CB911103, 2011CB5048002, 2012ZX10001006-003 and 2013ZX10001005-002), from National Natural Science Foundation of China (81371808, 81301439, 81401673 and 81528012), from National Key Plan for Scientific Research and Development of China (2016YFD0500300) and Canadian Institutes of Health Research (CIHR-132561).

Author Contributions

F.G. conceived and designed the experiments. F.X., X.Z., S.H., J.L., L.Y., S.M., T.L. and Y.W. conducted the experiment. L.R., S.C., Z.Z., J.W. and Q.J. contributed samples and materials. C.L. and B.A. wrote the manuscript and analyzed the data. All authors read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Xu, F. et al. Amphotericin B Inhibits Enterovirus 71 Replication by Impeding Viral Entry. Sci. Rep. 6, 33150; doi: 10.1038/srep33150 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016